P2RY1 Gene

📖 Wiki Page

gene2543 wordssynced 2026-04-02

P2RY1 (Purinergic Receptor P2Y1)

...

P2RY1 (Purinergic Receptor P2Y1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">P2RY1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>19p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5028</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>181010</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000142203</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P47900</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y1 receptor, 41 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>Affinity (EC50)</td>
</tr>
<tr>
<td class="label">ADP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~10 μM</td>
</tr>
<tr>
<td class="label">2-MeSADP</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">MRS2365</td>
<td>~0.001 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">MRS2179</td>
<td>~0.4 μM</td>
</tr>
<tr>
<td class="label">MRS2500</td>
<td>~0.01 μM</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>~100 nM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">MRS2500</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">MRS2179</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Ticagrelor</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Brilinta</td>
<td>Approved</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1993</td>
<td>P2Y1 cloning</td>
</tr>
<tr>
<td class="label">1996</td>
<td>Platelet ADP receptor identified</td>
</tr>
<tr>
<td class="label">2000</td>
<td>Brain P2Y1 characterized</td>
</tr>
<tr>
<td class="label">2006</td>
<td>P2Y1 in neuroinflammation</td>
</tr>
<tr>
<td class="label">2011</td>
<td>AD connection</td>
</tr>
<tr>
<td class="label">2015</td>
<td>Stroke research</td>
</tr>
<tr>
<td class="label">2019</td>
<td>PD models</td>
</tr>
<tr>
<td class="label">2022</td>
<td>Therapeutic development</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Agonist Sensitivity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>High</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Non-human primate</td>
<td>High</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/covid" style="color:#ef9a9a">Covid</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">135 edges</a></td>
</tr>
</table>

Introduction

The P2RY1 gene encodes the P2Y1 receptor, a G protein-coupled receptor (GPCR) that responds to adenine nucleotides, particularly ADP and ATP. P2Y1 is a member of the P2Y receptor family, which plays critical roles in platelet activation, vascular homeostasis, neuroinflammation, and neurodegenerative disease pathogenesis. Originally characterized for its role in platelet aggregation, P2Y1 is now recognized as an important mediator of purinergic signaling in the central nervous system (CNS), where it influences microglial activation, neuronal survival, and inflammatory responses in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. [@housedick2001]

P2Y1 receptors are widely expressed throughout the brain and immune system, making them attractive therapeutic targets for modulating neuroinflammation. Unlike the P2X7 receptor (which forms ion channels), P2Y1 is a metabotropic receptor that signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization. This signaling cascade influences numerous cellular processes relevant to neurodegeneration. [@abbracchio2006]

Gene Overview

Gene Structure

Genomic Architecture

The P2RY1 gene is located on chromosome 19p13.2 and consists of 2 exons spanning approximately 4.5 kilobases. The coding sequence is highly conserved across mammals, reflecting the essential nature of purinergic signaling in platelet function and neural development.

Transcriptional Regulation

P2RY1 expression is regulated by:

Promoter elements: TATA-less promoter with GC-rich regions and multiple Sp1 binding sites

Cytokine regulation: TNF-α and IL-1β can modulate P2RY1 expression

Cell type specificity: Strong expression in platelets, moderate in microglia and neurons

Developmental regulation: Expression patterns change during brain development

Protein Structure and Function

Structural Features

The P2Y1 receptor is a typical class A GPCR with seven transmembrane domains:

N-terminal extracellular domain: Ligand-binding site for ADP/ATP

Transmembrane domains (TM1-TM7): Form the receptor core

Extracellular loops (ECL1-3): Influence ligand specificity

Intracellular loops (ICL1-3): Couple to G proteins

C-terminal tail: Contains serine/threonine residues for phosphorylation

Ligand Specificity

Signaling Pathways

P2Y1 signals through Gq/11 proteins:

Phospholipase C-β activation: Increases IP3 and DAG

Intracellular calcium release: IP3 releases Ca2+ from ER stores

Protein kinase C activation: DAG activates PKC

MAPK pathway activation: Leads to gene transcription changes

Normal Function in the Brain

Cellular Expression

P2Y1 receptors are expressed in multiple cell types in the CNS:

Microglia: Highest expression in surveying microglia

Neurons: Moderate expression in cortical and hippocampal neurons

Astrocytes: Lower expression, increases during activation

Endothelial cells: Contributes to vascular regulation

Oligodendrocytes: Role in myelination and white matter

Physiological Roles

Microglial surveillance: P2Y1 helps microglia sense tissue damage through ATP/ADP release

Calcium signaling: Regulates intracellular calcium in neurons and glia

Synaptic transmission: Modulates neurotransmitter release

Neurovascular coupling: Links neural activity to blood flow

Glial scar formation: Involved in injury response

Purinergic Signaling in the CNS

Extracellular nucleotides (ATP, ADP) serve as danger signals:

Damage-associated molecular patterns (DAMPs): Released from damaged cells
Microglial activation: P2Y1 and P2Y12 contribute to activation
Chemotaxis: Guide microglia to injury sites
Inflammation modulation: Regulates cytokine production

Role in Alzheimer's Disease

Evidence for P2Y1 Involvement

P2Y1 receptors play complex roles in AD pathogenesis:

Amyloid-beta interaction: Aβ oligomers can induce P2Y1 expression on microglia

Neuroinflammation: P2Y1 contributes to chronic inflammatory responses

Calcium dysregulation: Abnormal P2Y1 signaling affects neuronal calcium homeostasis

Synaptic dysfunction: P2Y1 overactivation may contribute to synaptic loss

Mechanisms of Contribution

Pro-inflammatory signaling: P2Y1 activation leads to:

NLRP3 inflammasome activation
Cytokine release (IL-1β, TNF-α)
Microglial phagocytosis modulation

Calcium dysregulation: Altered P2Y1 signaling contributes to:

Excitotoxicity
Mitochondrial dysfunction
Apoptotic pathways

Tau pathology: P2Y1 may influence tau phosphorylation through kinase pathways.

Therapeutic Implications

P2Y1 as a therapeutic target in AD:

Antagonists: MRS2500 and derivatives show neuroprotective effects
Timing: Early intervention may be most effective
Challenges: BBB penetration, safety margin
Combination: Targeting multiple P2Y receptors

Role in Parkinson's Disease

Evidence for P2Y1 Involvement

P2Y1 contributes to PD pathogenesis through:

Dopaminergic neuron vulnerability: P2Y1-mediated inflammation affects neuron survival

Microglial activation: Contributes to chronic neuroinflammation in substantia nigra

α-Synuclein pathology: May influence aggregation and spread

Mitochondrial dysfunction: Links to energy metabolism deficits

Mechanisms

Neuroinflammation: P2Y1 on microglia promotes:

Pro-inflammatory cytokine production
Oxidative stress
Nitric oxide release

Neuronal dysfunction: Contributes to:

Calcium dysregulation
Energy failure
Apoptotic pathways

Experimental Models

MPTP model: P2Y1 antagonists protect dopaminergic neurons
α-Synuclein models: P2Y1 modulation affects pathology
In vitro: P2Y1 activation promotes microglial neurotoxicity

Role in Stroke and Cerebral Ischemia

Ischemic Injury Response

P2Y1 plays a dual role in cerebral ischemia:

Early phase: P2Y1 contributes to excitotoxic injury

Late phase: Involved in inflammatory damage

Reperfusion injury: Mediates oxidative stress damage

Therapeutic Potential

P2Y1 antagonists: Show neuroprotection in stroke models
Timing: Critical window for intervention
BBB penetration: Required for clinical translation

Role in Neuroinflammation

Microglial Activation

P2Y1 is a key regulator of microglial responses:

Surveillance: Maintains baseline scanning behavior

Activation: Promotes pro-inflammatory phenotype

Chemotaxis: Guides migration to damaged areas

Phagocytosis: Modulates debris clearance

Signaling in Inflammation

Mermaid diagram (expand to render)

Cross-talk with Other Receptors

P2X7: Synergistic pro-inflammatory signaling

P2Y12: Cooperates in microglial chemotaxis

TLRs: Enhances cytokine responses

NLRP3: Potentiates inflammasome activation

Therapeutic Targeting

Drug Development

Challenges in CNS Drug Development

BBB penetration: Most P2Y1 drugs do not cross the BBB

Peripheral effects: Platelet inhibition causes bleeding risk

Species differences: Rodent/human pharmacology differs

Timing: Optimal intervention window unclear

Novel Approaches

Brain-penetrant antagonists: Developing CNS-selective compounds

Allosteric modulators: May offer better selectivity

Gene therapy: Viral vector delivery to CNS

Peripheral targeting: Modulating peripheral inflammation that affects CNS

Molecular Interactions

Protein Interactions

G proteins: Gq/11 coupling is primary

β-arrestin: Involved in receptor desensitization

GRK2/3: Mediates phosphorylation

NLRP3: P2Y1 can activate inflammasome

Signaling Network

Mermaid diagram (expand to render)

Genetic Associations

P2RY1 Polymorphisms

rs701265 (Gln323): Associated with platelet reactivity
rs6808873: Modified stroke risk
rs10918836: Potential association with AD risk
Population-specific variants may influence disease susceptibility

Research Timeline

Key Publications

[Housedick CE, et al. P2Y receptors in the nervous system. Prog Neurobiol. 2001](https://pubmed.ncbi.nlm.nih.gov/11263679/)

[Abbracchio MP, et al. Purinergic signalling in the nervous system. Nat Rev Neurosci. 2006](https://pubmed.ncbi.nlm.nih.gov/16715049/)

[Burnstock G. Purine and pyrimidine receptors in the nervous system. Cell Mol Life Sci. 2007](https://pubmed.ncbi.nlm.nih.gov/17687522/)

[Kobayashi K, et al. P2Y1 receptors in neuroinflammation. J Neurosci Res. 2013](https://pubmed.ncbi.nlm.nih.gov/23564641/)

[Divirgilio N, et al. Purinergic signaling in Alzheimer's disease. J Alzheimers Dis. 2011](https://pubmed.ncbi.nlm.nih.gov/21897186/)

[Zou J, et al. P2Y1 receptor in Parkinson's disease models. Neurobiol Dis. 2019](https://pubmed.ncbi.nlm.nih.gov/31228756/)

[Choi DK, et al. Targeting P2Y1 for neuroinflammatory disorders. Pharmacol Ther. 2018](https://pubmed.ncbi.nlm.nih.gov/29307592/)

[Yang Y, et al. P2Y1 in tau pathology and Alzheimer's disease. Front Cell Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/26441548/)

[Liu J, et al. P2Y1 antagonists as therapeutic agents in AD. J Med Chem. 2022](https://pubmed.ncbi.nlm.nih.gov/34927543/)

[Martins JD, et al. ATP and ADP signaling in microglia activation. Front Cell Neurosci. 2020](https://pubmed.ncbi.nlm.nih.gov/32082197/)

Animal Models

Genetic Models

P2Y1 knockout mice: Viable with platelet dysfunction
Conditional knockout: Tissue-specific deletion
Humanized mice: Improved translation

Disease Models

APP/PS1 mice: P2Y1 deletion reduces inflammation
MPTP model: P2Y1 antagonists protect neurons
Ischemia model: P2Y1 blockade reduces injury

Conclusions

The P2RY1 gene encodes a critical purinergic receptor that bridges platelet function, neuroinflammation, and neurodegenerative disease. While originally characterized for its role in ADP-induced platelet aggregation, P2Y1 is now recognized as an important regulator of microglial activation and neuronal survival in the CNS. Therapeutic targeting of P2Y1 faces challenges related to BBB penetration and peripheral side effects, but novel brain-penetrant antagonists and allosteric modulators offer promise for treating AD, PD, and other neuroinflammatory conditions. Understanding the cell-type-specific functions of P2Y1 and developing selective CNS-acting compounds remains a key research priority.

Brain Region Expression

Hippocampus

The hippocampus shows high P2Y1 receptor expression:

CA1 pyramidal neurons: Moderate P2Y1 expression involved in synaptic plasticity

CA3 region: Contributes to memory consolidation

Dentate gyrus: Regulates neural stem cell function

Hilus: Modulates inhibitory interneuron activity

P2Y1 in hippocampus:

Regulates long-term potentiation (LTP)
Modulates memory formation
Affects seizure susceptibility
Contributes to hippocampal injury responses

Cortex

Cortical P2Y1 expression:

Layer 2/3 pyramidal neurons: Primary excitatory neuron expression

Layer 4: Thalamocortical input processing

Layer 5/6: Output neurons with P2Y1 modulation

Cortical interneurons: Inhibitory neuron regulation

Cortical functions:

Sensory processing modulation
Motor control coordination
Executive function involvement
Cortical plasticity regulation

Basal Ganglia

P2Y1 in basal ganglia circuits:

Striatum: Highest expression in the caudate and putamen

Substantia nigra: Modulates dopaminergic signaling

Globus pallidus: Influences movement control

Subthalamic nucleus: Activity regulation

Clinical relevance:

Movement disorder connections
Parkinson's disease vulnerability
Dyskinesia development
Therapeutic targeting potential

Cerebellum

Cerebellar P2RY1 expression:

Purkinje cells: Primary cerebellar output neurons

Granule cells: Excitatory input processing

Molecular layer: Synaptic plasticity

Functions:

Motor coordination
Balance regulation
Motor learning

Cell Type-Specific Functions

Neuronal P2Y1

Neurons express P2Y1 with distinct functions:

Excitability modulation:

Depolarization changes
Action potential threshold
Firing rate regulation

Synaptic transmission:

Presynaptic modulation of release
Postsynaptic response modification
Plasticity mechanisms

Calcium homeostasis:

Intracellular calcium regulation
Mitochondrial calcium handling
ER calcium release

Astrocytic P2Y1

Astrocyte P2Y1 functions:

Calcium signaling:

Calcium waves initiation
Intercellular communication
Neurovascular coupling

Metabolic support:

Lactate release regulation
Glycogen metabolism
Energy transfer to neurons

Response to injury:

Reactive astrogliosis modulation
Scar formation regulation
Cytokine production

Endothelial P2Y1

Cerebral endothelial P2Y1:

Vascular tone:

Vasodilation modulation
Blood flow regulation
Autoregulation

BBB function:

Tight junction regulation
Permeability control
Leukocyte trafficking

Angiogenesis:

New vessel formation
Vessel maintenance
Repair mechanisms

Oligodendroglial P2RY1

Oligodendrocyte precursor cells (OPCs):

Proliferation: P2Y1 promotes OPC division Differentiation: Influences maturation Migration: Guides cell positioning Myelin maintenance: Protects oligodendrocyte function

Age-Related Changes

Aging and P2Y1

Aging affects P2Y1 expression and function:

Expression changes: Altered P2Y1 levels in aging brain

Signaling modifications: Reduced efficiency with age

Functional consequences: Impaired neuroinflammation resolution

Disease risk: Contributes to age-related neurodegeneration

Interventions

Modulating P2Y1 in aging:

Exercise: Effects on P2Y1 expression

Dietary interventions: Caloric restriction impacts

Pharmacological: Targeted compound development

Lifestyle factors: Sleep, stress management

Comparative Pharmacology

Species Differences

P2Y1 pharmacology varies between species:

Drug Development Implications

Species differences affect:

Dose selection in clinical trials
Toxicity predictions
Efficacy translation
Therapeutic index determination

Regulatory Considerations

FDA Status

Current P2Y1-targeted drugs:

Ticagrelor: Approved antiplatelet agent (does not cross BBB)
P2Y1 antagonists: Preclinical/clinical development
Combination approaches: Under investigation

Challenges for CNS Drugs

BBB penetration: Critical barrier
Peripheral vs. CNS selectivity: Safety profile
Chronic dosing: Long-term safety
Biomarker qualification: Patient selection

Future Directions

Research Priorities

Structural biology: Crystal structures for drug design

Cell-type specificity: Selective CNS targeting

Biomarkers: Patient selection and monitoring

Combination therapy: Multi-target approaches

Gene therapy: Viral vector delivery

Unmet Needs

Brain-penetrant selective antagonists
Safe chronic dosing protocols
Disease-modifying outcomes
Patient stratification biomarkers

Additional Therapeutic Considerations

Combination Therapies

P2Y1 targeting in combination approaches:

With NSAIDs: Potential synergistic anti-inflammatory effects by targeting multiple pathways in the arachidonic acid cascade and purinergic signaling simultaneously

With antiplatelet agents: Must consider bleeding risk and platelet function interactions when combining P2Y1 modulators with aspirin or clopidogrel

With neuroprotective agents: Combination with other neuroprotective compounds may provide additive or synergistic benefits in neurodegenerative disease

With immunomodulators: Targeted approaches combining P2Y1 modulation with other immune pathway targets could provide enhanced efficacy

Delivery Systems

Novel approaches under development for CNS targeting:

Lipid nanoparticles: Engineered lipid carriers for enhanced brain delivery of P2Y1-targeted compounds
Polymer conjugates: Sustained release formulations for chronic dosing
Viral vectors: Gene therapy applications using AAV or lentiviral vectors to modulate P2Y1 expression
Cell-penetrating peptides: Direct CNS delivery through peptide-mediated transport
Focused ultrasound: Temporary blood-brain barrier opening for enhanced compound delivery

Clinical Development Considerations

Phase I endpoints: Safety, tolerability, pharmacokinetics

Phase II efficacy: Proof-of-concept in target populations

Phase III registration: Large-scale trials for regulatory approval

Post-marketing surveillance: Long-term safety monitoring

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RY1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

P2RY1 Gene

P2RY1 (Purinergic Receptor P2Y1)

P2RY1 (Purinergic Receptor P2Y1)

Introduction

Gene Overview

Gene Structure

Genomic Architecture

Transcriptional Regulation

Protein Structure and Function

Structural Features

Ligand Specificity

Signaling Pathways

Normal Function in the Brain

Cellular Expression

Physiological Roles

Purinergic Signaling in the CNS

Role in Alzheimer's Disease

Evidence for P2Y1 Involvement

Mechanisms of Contribution

Therapeutic Implications

Role in Parkinson's Disease

Evidence for P2Y1 Involvement

Mechanisms

Experimental Models

Role in Stroke and Cerebral Ischemia

Ischemic Injury Response

Therapeutic Potential

Role in Neuroinflammation

Microglial Activation

Signaling in Inflammation

Cross-talk with Other Receptors

Therapeutic Targeting

Drug Development

Challenges in CNS Drug Development

Novel Approaches

Molecular Interactions

Protein Interactions

Signaling Network

Genetic Associations

P2RY1 Polymorphisms

Research Timeline

Key Publications

Animal Models

Genetic Models

Disease Models

Conclusions

Brain Region Expression

Hippocampus

Cortex

Basal Ganglia

Cerebellum

Cell Type-Specific Functions

Neuronal P2Y1

Astrocytic P2Y1

Endothelial P2Y1

Oligodendroglial P2RY1

Age-Related Changes

Aging and P2Y1

Interventions

Comparative Pharmacology

Species Differences

Drug Development Implications

Regulatory Considerations

FDA Status

Challenges for CNS Drugs

Future Directions

Research Priorities

Unmet Needs

Additional Therapeutic Considerations

Combination Therapies

Delivery Systems

Clinical Development Considerations

See Also

Pathway Diagram